{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"groups":[{"description":"Participants were planned to receive TAK-981 recommended phase 2 dose (RP2D), infusion, intravenously, in combination with an anti-CD38 antibody (mezagitamab or daratumumab and hyaluronidase-fihj), injection, subcutaneously, for up to 24 cycles or until disease progression or unacceptable toxicity, or until any other discontinuation criterion is met, whichever occurs first. Each Cycle length was 28 days.","id":"OG000","title":"Phase 2: TAK-981 (RP2D) + Selected Anti-CD38 Antibody"}],"populationDescription":"The study was terminated after completion of Phase 1b Part 1, therefore, no participants were enrolled in Phase 2 part of the study. Hence, the data for this outcome measure could not collected, analyzed and reported.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Phase 2: Minimal Residual Disease (MRD) Negative Rate","type":"SECONDARY"}